Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Encouraging Early Results from the First in-Human Clinical Trial of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory B-Cell Lineage Non-Hodgkin Lymphoma

Brad S Kahl, MD, Mehdi Hamadani, MD, Paolo Caimi, MD, Carmelo Carlo-Stella, MD, Erin Reid, MD, Jay Feingold, MD PhD, Kirit M Ardeshna, MD, John Radford, MD, Melhem M Solh, MD, Ki-Young Chung, MD, Leonard Heffner, MD, Shui He, PhD, Joseph Boni, PhD, Owen Anthony O'Connor, MD

Blood (2017) 130 (Supplement 1): 187.

https://doi.org/10.1182/blood.V130.Suppl_1.187.187

Published: 2017

Journal Articles

Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (AdvSM)

Daniel J. DeAngelo, MD, Albert Thomas Quiery, MD, Deepti Radia, MD, Mark W Drummond, MB ChB, PhD FRCPath, Jason Gotlib, MD, William A Robinson, MD PhD, Elizabeth Hexner, MDMS, Srdan Verstovsek, MD PhD, Hongliang Shi, Terri Alvarez-Diez, Oleg Schmidt-Kittler, Erica Evans, PhD, Mary Ellen Healy, Beni B. Wolf, MD PhD, Michael W. Deininger, MD PhD

Blood (2017) 130 (Supplement 1): 2.

https://doi.org/10.1182/blood.V130.Suppl_1.2.2

Published: 2017

Journal Articles

Efficacy and Safety of Generic Imatinib after Switching from Innovator Imatinib in Patients Treated for Chronic Myeloid Leukemia

Iman Aboudalle, MD, Hagop M. Kantarjian, MD, Jan A. Burger, MD PhD, Zeev Estrov, MD, Maro Ohanian, DO, Elias J. Jabbour, MD, Srdan Verstovsek, MD PhD, Farhad Ravandi, MBBS, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 2906.

https://doi.org/10.1182/blood.V130.Suppl_1.2906.2906

Published: 2017

Journal Articles

Comparative Risk Assessment of Imatinib, Nilotinib and Dasatinib in Randomized Controlled Trials: A Meta-Analysis

Ahmad Ghorab, MDMSc, Hagop M. Kantarjian, MD, Hesham Elhalawani, MD MS, Hoda Ahmed, MD MS, Ahmed Essam, MD, Omar Abdel-Rahman, MD PhD, Elias J. Jabbour, MD, Jorge E. Cortes, MD

Blood (2017) 130 (Supplement 1): 2869.

https://doi.org/10.1182/blood.V130.Suppl_1.2869.2869

Published: 2017

Journal Articles

Crenolanib, a Type I FLT3 TKI, Can be Safely Combined with Cytarabine and Anthracycline Induction Chemotherapy and Results in High Response Rates in Patients with Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia (AML)

Eunice S. Wang, MD, Richard M. Stone, MD, Martin S. Tallman, MD, Roland B. Walter, MD PhD, John R. Eckardt, MD, Robert Collins

Blood (2016) 128 (22): 1071.

https://doi.org/10.1182/blood.V128.22.1071.1071

Published: 2016

Journal Articles

Dasatinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP) with Persistent, Low-Grade Nonhematologic Toxicity to Imatinib: Results from Dasperse (CA180-400)

Dong-Wook Kim, Charles S. Cleeland, PhD, Susanne Saussele, Loretta A. Williams, PhD APRN, Hesham Mohamed, Javier Pinilla-Ibarz, Elisabetta Abruzzese, MD

Blood (2015) 126 (23): 1575.

https://doi.org/10.1182/blood.V126.23.1575.1575

Published: 2015

Journal Articles

Safety and Efficacy of Total Dose Infusion of Low Molecular Weight (LMW) Iron Dextran in a Large Population of Anemic Patients Across a Broad Spectrum of Diagnoses Associated with Iron Lack

Tahir Mehmood, MD, Khine Swe, MD, Gopimohan Das, MD, Aysegul Gozu, MD MPH, Michael Auerbach, MD, Sein Aung, MD

Blood (2014) 124 (21): 4028.

https://doi.org/10.1182/blood.V124.21.4028.4028

Published: 2014

Journal Articles

Efficacy and Tolerability of Bosutinib and Imatinib in Older Versus Younger Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia–BELA Trial

Carlo Gambacorti-Passerini, Tim H Brümmendorf, Dong-Wook Kim, Irina Dyagil, Hagop M Kantarjian, Dmitri Pavlov, Karin Gogat, Ladan Duvillie, Mark Shapiro, Jorge E Cortes, MD

Blood (2012) 120 (21): 4442.

https://doi.org/10.1182/blood.V120.21.4442.4442

Published: 2012

Journal Articles

Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party

Blood (2011) 118 (21): 453.

https://doi.org/10.1182/blood.V118.21.453.453

Published: 2011

Journal Articles

Bosutinib Versus Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia – BELA Trial: 24-Month Follow-up

Jorge E Cortes, Anish Maru, Carmino Antonio Antonio De Souza, PhD, François Guilhot, Ladan Duvillie, Christine Powell, Athena Countouriotis, Carlo Gambacorti-Passerini, MD

Blood (2011) 118 (21): 455.

https://doi.org/10.1182/blood.V118.21.455.455

Published: 2011

Journal Articles

Safety and Management of Toxicities in the BELA Trial of Bosutinib Versus Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Carlo Gambacorti-Passerini, MD, Jorge E Cortes, Patricia Harris, Christine Powell, Athena Countouriotis, Hagop M Kantarjian

Blood (2011) 118 (21): 1685.

https://doi.org/10.1182/blood.V118.21.1685.1685

Published: 2011

Journal Articles

Differences in Haematological and Non Haematological Toxicity during Treatment with Imatinib in Early and Late Chronic Phase Chronic Myeloid Leukemia Patients

Massimo Breccia, Roberto Latagliata, Laura Cannella, Ida Carmosino, Caterina Stefanizzi, Michelina Santopietro, Giuliana Alimena

Blood (2008) 112 (11): 4281.

https://doi.org/10.1182/blood.V112.11.4281.4281

Published: 2008

Journal Articles

Hodgkin Disease and Nephrotic Syndrome, a Rare Paraneoplastic Complication in Children with Literature Review

Sehba Dsilva, MD, Gungor Karayalcin, MD, Sharon Singh, MD

Blood (2008) 112 (11): 4832.

https://doi.org/10.1182/blood.V112.11.4832.4832

Published: 2008

Journal Articles

Multicenter Experience with Imatinib Mesylate in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients.

A.M. Carella, MD, E. Lerma, MD, E. Orlandi, MD, M. Lazzarino, MD, M. Annunziata, MD, F. Ferrara, MD, E. Pungolino, MD, E. Morra, MD, M. Miglino, MD, M. Gobbi, MD

Blood (2007) 110 (11): 4554.

https://doi.org/10.1182/blood.V110.11.4554.4554

Published: 2007

Journal Articles

Bortezomid-Induced Sweet Syndrome.

Aline A. Schmidt-Tanguy, MD, Martine M. Avenel-Audran, MD, Séverine S. Lissandre, MD, Mammoun M. Dib, MD, Anne A. Croue, MD, Marie-Pierre M.P. Moles, MD, Norbert N. Ifrah, MD PhD, Mathilde M. Hunault-Berger, MD PhD

Blood (2006) 108 (11): 5128.

https://doi.org/10.1182/blood.V108.11.5128.5128

Published: 2006

Journal Articles

A Prospective Analysis of Adverse Events in a Phase 2 Trial of Imatinib in the Treatment of Polycythemia Vera.

C. Michael Jones, MD, Tina M. Dickinson, MSN, FNP

Blood (2005) 106 (11): 4951.

https://doi.org/10.1182/blood.V106.11.4951.4951

Published: 2005

NARROW

Encouraging Early Results from the First in-Human Clinical Trial of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory B-Cell Lineage Non-Hodgkin Lymphoma

Clinical Activity in a Phase 1 Study of Blu-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (AdvSM)

Efficacy and Safety of Generic Imatinib after Switching from Innovator Imatinib in Patients Treated for Chronic Myeloid Leukemia

Comparative Risk Assessment of Imatinib, Nilotinib and Dasatinib in Randomized Controlled Trials: A Meta-Analysis

Crenolanib, a Type I FLT3 TKI, Can be Safely Combined with Cytarabine and Anthracycline Induction Chemotherapy and Results in High Response Rates in Patients with Newly Diagnosed FLT3 Mutant Acute Myeloid Leukemia (AML)

Dasatinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CML-CP) with Persistent, Low-Grade Nonhematologic Toxicity to Imatinib: Results from Dasperse (CA180-400)

Safety and Efficacy of Total Dose Infusion of Low Molecular Weight (LMW) Iron Dextran in a Large Population of Anemic Patients Across a Broad Spectrum of Diagnoses Associated with Iron Lack

Efficacy and Tolerability of Bosutinib and Imatinib in Older Versus Younger Patients with Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia–BELA Trial

Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party

Bosutinib Versus Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia – BELA Trial: 24-Month Follow-up

Safety and Management of Toxicities in the BELA Trial of Bosutinib Versus Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

Differences in Haematological and Non Haematological Toxicity during Treatment with Imatinib in Early and Late Chronic Phase Chronic Myeloid Leukemia Patients

Hodgkin Disease and Nephrotic Syndrome, a Rare Paraneoplastic Complication in Children with Literature Review

Multicenter Experience with Imatinib Mesylate in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients.

Bortezomid-Induced Sweet Syndrome.

A Prospective Analysis of Adverse Events in a Phase 2 Trial of Imatinib in the Treatment of Polycythemia Vera.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only